SeaStar Medical (NASDAQ:ICU) vs. CochLear (OTCMKTS:CHEOY) Head-To-Head Analysis

CochLear (OTCMKTS:CHEOY) and SeaStar Medical (NASDAQ:ICU) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Institutional and Insider Ownership

1.7% of SeaStar Medical shares are owned by institutional investors. 0.7% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for CochLear and SeaStar Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CochLear	0	5	0	1	2.33
SeaStar Medical	1	0	1	0	2.00

CochLear currently has a consensus price target of $117.00, indicating a potential upside of 199.69%. SeaStar Medical has a consensus price target of $8.00, indicating a potential upside of 113.33%. Given CochLear’s stronger consensus rating and higher probable upside, equities research analysts plainly believe CochLear is more favorable than SeaStar Medical.

Earnings & Valuation

This table compares CochLear and SeaStar Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CochLear	$1.53 billion	3.35	$251.85 million	N/A	N/A
SeaStar Medical	$1.23 million	12.20	-$12.15 million	($4.80)	-0.78

CochLear has higher revenue and earnings than SeaStar Medical.

Profitability

This table compares CochLear and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CochLear	N/A	N/A	N/A
SeaStar Medical	-828.62%	-146.29%	-96.48%

Volatility and Risk

CochLear has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.05, suggesting that its stock price is 205% less volatile than the S&P 500.

Summary

CochLear beats SeaStar Medical on 9 of the 13 factors compared between the two stocks.

About CochLear

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.